Eye on Pharma: Good News, Bad News for Alvotech; EpiVax Secures FDA Grant for Biosimilar Testing
As Alvotech’s biosimilars are included in a commercialization deal in the Philippines, the company hits a setback in its quest for FDA approval of its adalimumab biosimilar; the FDA gives EpiVax a $2 million grant to run immunogenicity testing for biosimilars.
As Alvotech’s biosimilars are included in a commercialization deal in the Philippines, the company hits a setback in its quest for FDA approval of its adalimumab biosimilar; the FDA gives EpiVax a $2 million grant to run immunogenicity testing for biosimilars.
Alvotech Gets Bad News and Good News
Reykjavik, Iceland–based Alvotech received a complete response letter (CRL) from the FDA for its biologics license application (BLA) for AVT02, the company’s adalimumab biosimilar referencing Humira.
The letter focused on a filed manufacturing facility inspection in March 2022. The CRL noted “deficiencies related to the Reykjavik facility and states that satisfactory resolution of the deficiencies is required before FDA may approve this BLA,” according to Alvotech’s statement.
Alvotech expressed that it will address the issues mentioned in the CRL and will continue to work with the FDA to complete the facility inspection. Mark Levick, Alvotech’s CEO, said that it still anticipates to get approval prior to its planned July 1, 2023, US launch date.
The company is looking to obtain regulatory approval and an interchangeability designation for AVT02, and the FDA is currently reviewing BLAs for both. AVT02 is available in some European markets and Canada.
Additionally, some of Alvotech’s biosimilars have an opportunity to reach a new market. As part of a commercialization agreement between Lupin Limited and DKSH, patients in the Philippines will have access to 5 biosimilars developed by Alvotech. The agreement will apply for biosimilars referencing Prolia/Xgeva (denosumab), Simponi (golimumab), Eylea (aflibercept), and 2 undisclosed products.
Multicare Pharmaceuticals, Lupin’s subsidiary in the Philippines, will be responsible for obtaining marketing approval in the country and will have the distribution and commercialization rights for the biosimilars upon approval. The biosimilars will be used to treat several bone conditions, cancer types, immune conditions, and retinal diseases.
DKSH is one of Alvotech’s commercial partners in several Asian markets, including Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh, and Pakistan.
EpiVax Secures Funding for Immunogenicity Testing
EpiVax, a Providence, Rhode Island–based company, announced that it has received a 2-year, $2 million grant from the FDA’s Officer for Center for Drug Evaluation and Research (CDER) for immunogenicity testing of biosimilars.
The analyses will validate a method for immunogenicity risk assessment of host cell proteins (HCPs) for improving the development process of biosimilar candidates and assessing the interchangeability of biosimilars. EpiVax will begin its research in September 2022 and will finish in August 2024.
“[HCPs] have strong potential to enhance immunogenicity of biological therapeutics. Rapid and accurate methods for identifying of higher risk and lower risk HCP will permit drug developers to improve the safety profile of their biologic products,” said Amy Rosenberg, MD, senior director of immunogenicity of biological therapeutics at EpiVax, in a statement.
The grant will help EpiVax assess in silico tools for screening and triaging HCPs to see whether they “induce an unwanted immune response” in patients receiving a biosimilar. Preclinical validation of in silico tools and ensuring patient access to them could improve the safety of biologic drugs and accelerate the assessment process of immunogenicity risk for biosimilars.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
